Novo Nordisk A/S: Saxenda® approved in Europe for the treatment of obesity

Bagsværd, Denmark, 23 March 2015 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Saxenda® (liraglutide 3 mg) for the treatment of obesity. The authorisation covers all 28 European Union (EU) member states.